Medical Digest & Congress Report

Cho Han Chiang, MD, MMSc presented an analysis at the 2024 ASH Annual Meeting, that shows GLP-1 receptor agonists led to a significant reduction in the risk for VTE among individuals with type 2 diabetes, compared with DPP-4 inhibitors, a recent indicated. Video: https://medicaldigest.org/scientific-contents/interview:do-glp-1s-lower-vte-risk-people-type-2-diabetes

Rahul Banerjee, MD, FACP comments on the role of 24-hour urine testing in assessing multiple myeloma treatment responses at the 2024 ASH Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:24-hour-urine-testing-does-not-add-value-multiple-myeloma-response-assessments

Rahul Banerjee, MD, FACP discusses the state of the art treatment in Multiple Myeloma Care at the 2024 ASH Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:bridging-gaps-multiple-myeloma-care-community-oncologists-guide-navigating-evolving-treatment-landscape

Matthew S. Davids, MD, MMSc discusses the state of the art treatment in chronic lymphocytic leukemia at the 2024 ASH Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:crafting-custom-care-cll-guidance-upfront-and-sequential-treatment-decisions-targeted-and-immune-base-platforms

Anand A. Patel, MD discusses the state of the art treatment in adult acute lymphoblastic leukemia at the 2024 ASH Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:state-art-treatment-adult-all

Catherine S. Diefenbach, MD discusses the state of the art treatment in lymphoma care at the 2024 ASH Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:state-art-treatment-lymphoma

Prof. Francesco Passamonti discusses the state of the art treatment in myelofibrosis Care at the 2024 ASH Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:mastering-art-myelofibrosis-care-expert-guidance-clinical-experience-innovation-more-personalized-disease-control

Kerry A Rogers, MD discusses current questions and controversies in the management of chronic lymphocytic leukemia at the 2024 ASH Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:addressing-current-questions-and-controversies-management-chronic-lymphocytic-leukemia

Michael J. Mauro, MD discusses current questions and controversies in the management of chronic myeloid leukemia at the 2024 ASH Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:addressing-current-questions-and-controversies-management-chronic-myeloid-leukemia

Mikkael A. Sekeres, MD, MS discusses the state of the art treatment in MDS at the 2024 ASH Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:state-art-treatment-myelodysplastic-syndromes

Prof. Gilles Salles presented a 5-year analysis of the POLARIX study at the 2024 ASH Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:five-year-analysis-polarix-study

Prof. Gilles Salles discusses managing first relapse in diffuse large B-Cell lymphoma outside of CAR-Ts at the 2024 ASH Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:managing-first-relapse-diffuse-large-b-cell-lymphoma-outside-car-ts

Vaishali Sanchorawala, MD review the clinical challenges and intricacies of care associated with the management of light chain amyloidosis. Video: https://medicaldigest.org/scientific-contents/interview:unraveling-data-and-care-strategies-al-amyloidosis

Joshua Brody, MD discusses the advancing field of bispecific antibodies in third-line relapsed/refractory follicular lymphoma. Video: https://medicaldigest.org/scientific-contents/interview:bispecific-antibodies-playbook-relapsedrefractory-follicular-lymphoma

Sangeetha Venugopal MD,MS discusses that smoking intensity and duration in patients with myelodysplastic syndromes were tied to distinct genetic mutations, higher mutation burden, and worse survival outcomes, according to a study presented at the 2024 ASH Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:smoking-tied-worsened-disease-progression-myelodysplastic-syndrom...

Martin Hutchings, MD, PhD discusses the role of CAR T-Cell therapy and bispecific antibodies in the management of lymphoma at the 2024 ASH Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:addressing-current-questions-and-controversies-regarding-role-car-t-cell-therapy-and-bispecific-antibodies-management-lymphoma

Virginia Kaklamani, MD, DSc discusses estrogen receptor mutations in HR+ advanced breast cancer and generation practice recommendations on mutation screening to guide therapeutic decisions at San Antonio Breast Cancer Symposium 2024. Video: https://medicaldigest.org/scientific-contents/interview:estrogen-receptor-mutations-hr-advanced-breast-cancer-next-generation-practice-recommendations-mutation...

Nan Chen, MD explains patients with early-stage, node-negative, hormone receptor positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes when treated with adjuvant anthracycline- plus taxane-based chemotherapy regimens compared with those receiving adjuvant taxane-based chemotherapy regimens alone, according to results at S...

Heather McArthur, MD, MPH discusses immunotherapy panel discussion to explore inroads for ER-positive disease, challenges ahead at San Antonio Breast Cancer Symposium 2024. Video: https://medicaldigest.org/scientific-contents/interview:immunotherapy-explore-inroads-er-positive-disease-challenges-ahead

Sherene Loi, MD discusses immune biomarkers in early breast cancer at San Antonio Breast Cancer Symposium 2024. Video: https://medicaldigest.org/scientific-contents/interview:winding-road-immune-biomarkers-early-breast-cancer

Prof. Sibylle Loibl presented the findings from the phase 3 PADMA clinical trial at San Antonio Breast Cancer Symposium 2024. Video: https://medicaldigest.org/scientific-contents/interview:palbociclib-plus-endocrine-therapy-beats-chemo-hrher2-metastatic-breast-cancer

Shelley Hwang, MD, MPH discusses active monitoring instead of upfront surgery may be a viable option for patients with hormone receptor-positive, HER2-negative, low-risk DCIS, according to results presented at San Antonio Breast Cancer Symposium 2024. Video: https://medicaldigest.org/scientific-contents/interview:comet-trial-finds-active-monitoring-viable-option-some-patients-low-risk-dcis

Otto Metzger, MD presented late-breaking results of the phase 3 PATINA trial showing addition of CDK4/6 inhibitor palbociclib to standard therapy led to a 15-month improvement in PFS in HR+, HER2+ metastatic breast cancer at San Antonio Breast Cancer Symposium 2024. Video: https://medicaldigest.org/scientific-contents/interview:palbociclib-shows-benefit-hr-her2-metastatic-breast-cancer-patina-tria...

Matteo Lambertini, MD, PhD discusses an educational session focus on the management of breast cancer in young women at San Antonio Breast Cancer Symposium 2024. Video: https://medicaldigest.org/scientific-contents/interview:breast-cancer-young-women

Katherine L. Nathanson, MD discusses reversion mutations in BRCA1/2 in response to therapy at San Antonio Breast Cancer Symposium 2024. Video: https://medicaldigest.org/scientific-contents/interview:future-cancer-genetics-here-reversion-mutations-brca12-response-therapy